Lab
Tidalhealth Peninsula Regional, INC.
Tidalhealth Peninsula Regional, INC. was paid $3.16M by Medicaid between Jan 2018 and Sep 2024, across 104 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.
33Billing provider infoTIDALHEALTH PENINSULA REGIONAL, INC.
SALISBURY, MD 21801
SALISBURY, MD 21801
33aNPI1700984788assigned 09/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$3.16M
24GClaims227,028
24DCodes billed104
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Maryland
Rank by total paid#22 of 93
Median peer was paid$430K
This provider vs. median7.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,873 | $251.33 | |
| 2019 | 950 | $515.48 | |
| 2020 | 32,095 | $438K | |
| 2021 | 44,091 | $773K | |
| 2022 | 58,083 | $1.01M | |
| 2023 | 54,099 | $660K | |
| 2024incomplete | 35,837 | $280K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 22% | 8,125 | 7,234 | $698K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 10% | 885 | 782 | $318K |
| 80061 | Lipid panel | 5.0% | 15,958 | 12,886 | $158K |
| 80053 | Comprehensive metabolic panel | 4.9% | 22,885 | 17,717 | $155K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.7% | 8,558 | 6,657 | $147K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.6% | 6,176 | 3,438 | $145K |
| 84443 | Thyroid stimulating hormone (TSH) | 4.6% | 14,843 | 11,567 | $144K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 3.9% | 2,661 | 2,375 | $123K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.7% | 3,984 | 3,516 | $116K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.7% | 3,971 | 3,501 | $116K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.7% | 11,767 | 9,493 | $85K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.6% | 17,037 | 12,906 | $82K |
92 more codes
| 85027 | 1.5% | 9,364 | $48K | |
| 88342 | 1.4% | 1,153 | $43K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.3% | 1,826 | $42K |
| 84439 | 1.3% | 5,915 | $41K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.2% | 1,967 | $39K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.2% | 5,500 | $38K |
| 82607 | 1.2% | 4,271 | $37K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.1% | 1,459 | $35K |
| 86803 | 1.1% | 3,088 | $35K | |
| 84466 | <1% | 3,313 | $31K | |
| 82728 | <1% | 2,969 | $29K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,466 | $29K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 238 | $27K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 777 | $25K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,333 | $23K |
| 87070 | <1% | 3,499 | $23K | |
| 83540 | <1% | 3,601 | $17K | |
| 84153 | <1% | 1,313 | $17K | |
| 84702 | <1% | 1,382 | $16K | |
| 83655 | <1% | 1,600 | $15K | |
| 82746 | <1% | 2,259 | $15K | |
| 86140 | <1% | 3,503 | $15K | |
| 80050 | General health panel | <1% | 2,397 | $14K |
| 83735 | <1% | 3,275 | $14K | |
| 82043 | <1% | 2,952 | $13K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,875 | $13K |
| 86038 | <1% | 1,369 | $13K | |
| 84481 | <1% | 1,214 | $12K | |
| 87081 | <1% | 2,063 | $12K | |
| 87077 | <1% | 1,966 | $11K | |
| 87186 | <1% | 1,528 | $10K | |
| 88304 | <1% | 382 | $10K | |
| 81001 | <1% | 3,596 | $9K | |
| 80076 | <1% | 1,254 | $8K | |
| 86618 | <1% | 747 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 193 | $6K |
| 83970 | <1% | 202 | $5K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 138 | $5K |
| 85652 | <1% | 2,741 | $5K | |
| 84403 | <1% | 355 | $5K | |
| 83001 | <1% | 307 | $4K | |
| 85007 | <1% | 1,619 | $4K | |
| 80074 | <1% | 82 | $4K | |
| 85610 | <1% | 1,038 | $3K | |
| 83002 | <1% | 234 | $3K | |
| 86592 | <1% | 967 | $3K | |
| 86376 | <1% | 292 | $3K | |
| 81003 | <1% | 1,576 | $3K | |
| 87205 | <1% | 777 | $3K | |
| 84146 | <1% | 165 | $3K | |
| 87481 | <1% | 195 | $2K | |
| 82784 | <1% | 322 | $2K | |
| 84450 | <1% | 533 | $2K | |
| 86430 | <1% | 554 | $2K | |
| 84460 | <1% | 511 | $2K | |
| 82247 | <1% | 510 | $2K | |
| 85651 | <1% | 535 | $2K | |
| 86480 | <1% | 55 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 32 | $1K |
| 82670 | <1% | 51 | $1K | |
| 84480 | <1% | 96 | $1K | |
| 86706 | <1% | 97 | $941.38 | |
| 87340 | <1% | 106 | $882.34 | |
| 84550 | <1% | 236 | $763.14 | |
| 83690 | <1% | 125 | $735.43 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 119 | $702.52 |
| 82565 | <1% | 158 | $695.17 | |
| 84402 | <1% | 101 | $668.26 | |
| 87088 | <1% | 102 | $654.12 | |
| 83615 | <1% | 135 | $625.66 | |
| 82248 | <1% | 157 | $620.22 | |
| 88142 | <1% | 27 | $536.76 | |
| 86364 | <1% | 88 | $524.97 | |
| 87522 | Neg quan hep c or qual rna | <1% | 12 | $512.89 |
| 83880 | <1% | 16 | $497.75 | |
| 80069 | <1% | 56 | $467.18 | |
| 87420 | <1% | 77 | $448.97 | |
| 86200 | <1% | 50 | $439.42 | |
| 82533 | <1% | 48 | $425.84 | |
| 85730 | <1% | 92 | $411.36 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 30 | $383.19 |
| 84156 | <1% | 138 | $372.43 | |
| 83516 | <1% | 35 | $330.54 | |
| 86753 | <1% | 28 | $316.15 | |
| 83721 | <1% | 35 | $288.58 | |
| 82570 | <1% | 82 | $284.73 | |
| 86666 | <1% | 29 | $269.74 | |
| 84100 | <1% | 43 | $162.75 | |
| 83020 | <1% | 13 | $149.23 | |
| 86003 | <1% | 415 | $148.72 | |
| 85660 | <1% | 14 | $74.74 | |
| 85045 | <1% | 20 | $70.56 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRIFFIN, MICKEY (SENIOR DIRECTOR PFS)
| Provider | Location | Paid |
|---|---|---|
| Tidalhealth Peninsula Regional, INC. | Salisbury, MD | $120K |
| Tidalhealth Peninsula Regional, INC. | Salisbury, MD | $74K |
| Tidalhealth Peninsula Regional, INC. | Salisbury, MD | $706.25 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.